Skip to main content
. 2023 Jul 5;2023(7):CD006910. doi: 10.1002/14651858.CD006910.pub3

1.13. Analysis.

1.13

Comparison 1: Platinum‐sensitive recurrent EOC: PLD with chemotherapy versus alternative combination chemotherapy, Outcome 13: SevAE: Arthralgia/myalgia (grade ≥ 3)